adenosine (Adenocard, Adenoscan)

From Aaushi
Jump to navigation Jump to search

Introduction

Purine nucleoside & neurotransmitter.

Pharmacology

Tradename Adenocard. Indication(s):

Contraindications

pregnancy category = c

safety in lactation = ?

Dosage

  • 6 mg rapid IV
  • if no response after 1-2 min, give 12 mg
  • a 3rd dose of 12 mg may be given

* use at a reduced dose in patients with a history of cardiac transplantation

Pharmacokinetics

elimination via plasma

1/2life = 10 seconds

Adverse effects

Drug interactions

Mechanism of action

More general terms

More specific terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (ed), Companion Handbook, McGraw Hill, NY, 1994
  3. Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 163
  4. 4.0 4.1 Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  5. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  6. 6.0 6.1 6.2 Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 17. American College of Physicians, Philadelphia 2009, 2012, 2015
  7. FDA MedWatch. Nov 20, 2013 Lexiscan (regadenoson) and Adenoscan (adenosine): Drug Safety Communication - Rare but Serious Risk of Heart Attack and Death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm

Database